Myriad Medical's closing price on March 5, 2021 was 386.00 yuan, with a total market capitalization of 469.257 billion yuan and a price-to-earnings ratio of 73.64, which is derived by dividing the share price by the earnings per share, and can also be obtained by dividing the company's market capitalization by the net profit. It is one of the most commonly used indicators for stock valuation.
Currently more than 70 P/E ratio is high, but there are many factors affecting stock valuation, such as growth, dividend rates, assets and other tangible and intangible things, and some other factors, such as the proportion of shares held by major shareholders, the pressure of the release of the ban, etc., so whether the stock valuation is reasonable needs to be viewed comprehensively, can not be based on a particular data.
Myriad Medical, known as Shenzhen Myriad Biomedical Electronics Co., Ltd, founded in 1991, registered in Shenzhen Nanshan District Hi-Tech Industrial Park, Science and Technology, South 12th Road, Myriad Building, 1-4 floor, is the world's leading provider of medical equipment and solutions. Headquartered in Shenzhen, Myriad provides medical device products to the global market. It has subsidiaries in more than 30 provinces and autonomous regions in China.
Shenzhen Myriad BioMedical Electronics Co., Ltd.'s main business covers the three major areas of life information and support, in vitro diagnostics, and medical imaging, and through cutting-edge technological innovations, it provides better product solutions to help the world to improve medical conditions and enhance the efficiency of diagnosis and treatment.
Shenzhen Myriad Bio-medical Electronics Co., Ltd. has external investments in Beijing DeepMyriad Medical Electronics Technology Research Institute Co.